Credit: Shutterstock photoStealth BioTherapeutics, a Phase 3 biotech focused on rare diseases caused by mitochondrial dysfunction, raised $78 million by offering 6.5 million shares at $12, the low end of the range of $12 to $14. Stealth BioTherapeutics plans to list on the Nasdaq under the symbol MITO. Jefferies, Evercore ISI and BMO Capital Markets acted as lead managers on the deal.
The article Stealth BioTherapeutics prices IPO at $12, the low end of the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
